ESMO

Tanvex Presents Positive Findings for Trastuzumab Candidate at ESMO

September 20th 2021

Article

Investigators said TX05 met pathologic complete response criteria for equivalence to the originator product, Herceptin. The biosimilar candidate also fell within objective response rate, immunogenicity, safety, and tolerability margins for similarity.

Biocad's BCD-021 Bevacizumab Biosimilar Demonstrates Equivalence in NSCLC

September 17th 2021

Article

BCD-021 demonstrated equivalence in a phase 3 study involving Russian and Indian patients with advanced non–small cell lung cancer (NSCLC).

MIL60 Bevacizumab Biosimilar Candidate Demonstrates Equivalence in NSCLC

September 16th 2021

Article

MIL60 bevacizumab biosimilar candidate demonstrates equivalence to the originator Avastin in a population of Chinese patients with non–small cell lung cancer (NSCLC) treated in a frontline setting.

Samsung Bioepis Reports Long-term Ontruzant Findings for HER2-Positive Breast Cancer

September 14th 2021

Article

The positive findings for the trastuzumab biosimilar Ontruzant in patients with human epidermal growth factor receptor 2 (HER2)–positive early or locally advanced breast cancer were presented at the European Society for Medical Oncology (ESMO) Congress 2021.

Positive Clinical Trial Results for 2 Proposed Pegfilgrastim Biosimilars

October 25th 2018

Article

Pegfilgrastim, a long-acting granulocyte-colony stimulating factor (G-CSF) therapy, has become a key product for the prophylaxis and treatment of febrile neutropenia, and biosimilar options have the potential to reduce the high cost of pegfilgrastim therapy. At the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, 2 research teams presented on studies assessing proposed pegfilgrastim biosimilar products.

Biosimilar Epoetin Alfa Improves Both Hemoglobin Levels and Quality of Life

October 25th 2018

Article

Anemia is a common complication for patients who are undergoing chemotherapy, and one that has implications for patients’ quality of life, especially with respect to fatigue. During the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, Jérôme Desrame, MD, reported on results of the CIROCO study, which assessed fatigue in patients with chemotherapy-induced anemia who were treated with biosimilar epoetin alfa.

As Reassuring Data on Anticancer Biosimilars Grow, ESMO Ups Its Biosimilar Education

October 24th 2018

Article

The European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018, in Munich, Germany, featured multiple presentations on biosimilars in oncology, all of which are contributing to the body of evidence that points to the safety and efficacy of these products. Despite such reassuring data for biosimilars, however, many stakeholders have noted that lack of provider education on biosimilars is holding back progress with uptake.

Phase 3 Study Confirms Clinical Equivalence for ABP 980 and Reference Trastuzumab

October 4th 2017

Article

Complete phase 3 data show that a biosimilar almost beat reference trastuzumab (Herceptin) for the primary endpoint of pathologic complete response in patients with HER2-positive early breast cancer.

Ten Years of Clinical Experience With Biosimilar Epoetin Alfa HX575

September 12th 2017

Article

The epoetin alfa biosimilar HX575 (Binocrit, a product of Sandoz) was approved in the European Union in 2007 for the treatment of chemotherapy-induced anemia (CIA) and anemia associated with chronic renal failure.

Research Highlights Filgrastim and Pegfilgrastim Biosimilars

September 11th 2017

Article

Three posters presented on September 10, 2017, at the European Society for Medical Oncology (ESMO) 2017 meeting in Madrid, Spain, covered research on 2 proposed pegfilgrastim biosimilars and evaluated the use of filgrastim in oncology practice.